Michael Tanaka, MD

Clinical Professor

  • 1601 Citations
  • 11 h-Index
1980 …2017
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Michael Tanaka is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 16 Similar Profiles
irinotecan Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Paclitaxel Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Maximum Tolerated Dose Medicine & Life Sciences
Plasminogen Activators Medicine & Life Sciences
Carboplatin Medicine & Life Sciences
Pancreatic Neoplasms Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1980 2017

  • 1601 Citations
  • 11 h-Index
  • 20 Article
4 Citations (Scopus)

Phase II study of dovitinib in patients progressing on anti-vascular endothelial growth factor therapy

Semrad, T., Kim, E., Tanaka, M., Sands, J., Roberts, C., Burich, R. A., Li, Y., Gandara, D. R., Lara, P. N. & Mack, P., Jan 1 2017, In : Cancer Treatment and Research Communications. 10, p. 21-26 6 p.

Research output: Contribution to journalArticle

Vascular Endothelial Growth Factor A
Fibroblast Growth Factors
Therapeutics
Neoplasms
Lymphopenia
10 Citations (Scopus)

Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results

Semrad, T., Barzi, A., Lenz, H. J., Hutchins, I. M., Kim, E., Gong, I. Y., Tanaka, M., Beckett, L. A., Holland, W., Burich, R. A., Snyder-Solis, L., Mack, P. & Lara, P. N., Aug 5 2014, In : International Journal of Clinical Oncology. 20, 3, p. 518-524 7 p.

Research output: Contribution to journalArticle

gemcitabine
Tumor Biomarkers
Pancreatic Neoplasms
Kirsten murine sarcoma virus
Parvovirus
11 Citations (Scopus)

Escalating weekly doses of cetuximab and correlation with skin toxicity: A phase I study

Ho, C., Sangha, R., Beckett, L. A., Tanaka, M., Lau, D. H., Eisen, D. B., Burich, R. A., Luciw, P. A., Khan, I., Mack, P., Gandara, D. R. & Davies, A. M., Aug 2011, In : Investigational New Drugs. 29, 4, p. 680-687 8 p.

Research output: Contribution to journalArticle

Exanthema
Skin
Acne Vulgaris
Epidermal Growth Factor Receptor
Neoplasms
175 Citations (Scopus)

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

Ramanathan, R. K., Belani, C. P., Singh, D. A., Tanaka, M., Lenz, H. J., Yen, Y., Kindler, H. L., Iqbal, S., Longmate, J., Mack, P., Lurje, G., Gandour-Edwards, R. F., Dancey, J. & Gandara, D. R., Sep 2009, In : Cancer Chemotherapy and Pharmacology. 64, 4, p. 777-783 7 p.

Research output: Contribution to journalArticle

Biliary Tract
Liver Neoplasms
Disease-Free Survival
Neoplasms
Skin
712 Citations (Scopus)

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033

Blanke, C. D., Rankin, C., Demetri, G. D., Ryan, C. W., Von Mehren, M., Benjamin, R. S., Raymond, A. K., Bramwell, V. H. C., Baker, L. H., Maki, R. G., Tanaka, M., Randolph Hecht, J., Heinrich, M. C., Fletcher, C. D. M., Crowley, J. J. & Borden, E. C., Feb 1 2008, In : Journal of Clinical Oncology. 26, 4, p. 626-632 7 p.

Research output: Contribution to journalArticle

Gastrointestinal Stromal Tumors
Receptor Protein-Tyrosine Kinases
Disease-Free Survival
Survival
Imatinib Mesylate